Atlas Trials

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma

Clinical trial NCT01183429 · COMPLETED

Trial details

NCT number
NCT01183429
Sponsor
Memorial Sloan Kettering Cancer Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Neuroblastoma
Start date
2010-08-12
Primary completion
2018-09-13
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.